Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
US Army
UBS
Federal Trade Commission
Merck
Moodys
Farmers Insurance
Baxter
McKinsey

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,598,603

« Back to Dashboard

Which drugs does patent 6,598,603 protect, and when does it expire?


Patent 6,598,603 protects PULMICORT RESPULES and is included in one NDA. There have been two Paragraph IV challenges on Pulmicort Respules.

Protection for PULMICORT RESPULES has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,598,603

Title: Method for treating respiratory diseases
Abstract:The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer.
Inventor(s): Andersson; Bertil (Bjarred, SE), Conradsson; Thor-Bjorn (Sodra Sandby, SE), Eriksson; Goran (Dalby, SE)
Assignee: Astra Aktiebolag (SE)
Application Number:09/220,137
Patent Claim Types:
see list of patent claims
Use; Composition; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
PULMICORT RESPULES
budesonide
SUSPENSION;INHALATION020929-001Aug 8, 2000ANRXYesNo► Subscribe► SubscribeY
Astrazeneca Pharms
PULMICORT RESPULES
budesonide
SUSPENSION;INHALATION020929-002Aug 8, 2000ANRXYesNo► Subscribe► SubscribeY
Astrazeneca Pharms
PULMICORT RESPULES
budesonide
SUSPENSION;INHALATION020929-003Aug 8, 2000ANRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
AstraZeneca
Cipla
McKesson
Teva
US Army
Citi
Moodys
Fuji
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot